Immunogenicity and safety of BNT162b2 mRNA vaccine booster in actively treated patients with cancer

被引：32
|
作者：
Ligumsky, Hagai [1 ,6 ]
Dor, Herut [6 ]
Etan, Tal [1 ]
Golomb, Inbal [1 ,6 ]
Nikolaevski-Berlin, Alla [1 ]
Greenberg, Inbal [6 ]
Halperin, Tamar [2 ]
Angel, Yoel [3 ,6 ]
Henig, Oryan [4 ,6 ]
Spitzer, Avishay [1 ,6 ,7 ]
Slobodkin, Marina [5 ,6 ]
Wolf, Ido [1 ,6 ]
机构：
[1] Tel Aviv Sourasky Med Ctr, Oncol Div, IL-6423906 Tel Aviv, Israel
[2] Tel Aviv Sourasky Med Ctr, Human Immunodeficiency Virus Lab, IL-6423906 Tel Aviv, Israel
[3] Tel Aviv Sourasky Med Ctr, Dept Anasthesia Pain & Intens Care, IL-6423906 Tel Aviv, Israel
[4] Tel Aviv Sourasky Med Ctr, Dept Infect Dis & Infect Control, IL-6423906 Tel Aviv, Israel
[5] Tel Aviv Sourasky Med Ctr, Dept Internal Med D, IL-6423906 Tel Aviv, Israel
[6] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel
[7] Weizmann Inst Sci, Dept Mol Cell Biol, Rehovot, Israel
来源：
LANCET ONCOLOGY | 2022年 / 23卷 / 02期
关键词：
D O I：
10.1016/S1470-2045(21)00715-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：193 / 195
页数：3
相关论文
共 50 条
  • [1] Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine Among Actively Treated Cancer Patients
    Ligumsky, Hagai
    Safadi, Esraa
    Etan, Tal
    Vaknin, Noam
    Waller, Manuel
    Croll, Assaf
    Nikolaevski-Berlin, Alla
    Greenberg, Inbal
    Halperin, Tami
    Wasserman, Asaf
    Galazan, Lior
    Arber, Nadir
    Wolf, Ido
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2022, 114 (02): : 203 - 209
  • [2] Reduced immunogenicity of the mRNA vaccine BNT162b2 in patients with IPF
    Karampitsakos, T.
    Dimeas, I
    Tsiri, P.
    Sotiropoulou, V
    Tomos, I
    Papanikolaou, I
    Katsaras, M.
    Kirgou, P.
    Daniil, Z.
    Gourgoulianis, K.
    Papalexatos, D.
    Sampsonas, F.
    Manali, E.
    Papiris, S.
    Bouros, D.
    Tzouvelekis, A.
    Papaioannoui, o
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [3] Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Melanoma Treated with Immunotherapy
    Diamantopoulos, Panagiotis T.
    Kontandreopoulou, Christina-Nefeli
    Gkoufa, Aikaterini
    Solomou, Elena
    Anastasopoulou, Amalia
    Palli, Eleni
    Kouzis, Panagiotis
    Bouros, Spyros
    Samarkos, Mihalis
    Magiorkinis, Gkikas
    Gogas, Helen
    CANCERS, 2022, 14 (15)
  • [4] Immunogenicity and safety of the booster BNT162b2 vaccine in patients with axial spondyloarthritis treated with biological disease-modifying drugs
    Smetanova, Jitka
    Milota, Tomas
    Rataj, Michal
    Hurnakova, Jana
    Zelena, Hana
    Sediva, Anna
    Horvath, Rudolf
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [5] Immunogenicity of a BNT162b2 vaccine booster in health-care workers
    Saiag, Esther
    Goldshmidt, Hanoch
    Sprecher, Eli
    Ben-Ami, Ronen
    Bomze, David
    LANCET MICROBE, 2021, 2 (12): : E650 - E650
  • [6] Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers
    Rojkovich, Bernadette
    Nemeth, Dora
    Torok, Eszter
    Szabo, Bernadette
    Pinter, Agnes
    Juhasz, Istvan
    Weidl, Marton
    Lanyi, Eva
    Pavel-Szecsko, Judit
    Lazar, Imre
    Perduk, Andras
    Reiter, Jozsef
    Nagy, Gyorgy
    Nagy, Erzsebet
    Geher, Pal
    ORVOSI HETILAP, 2021, 162 (39) : 1551 - 1557
  • [7] Reduced immunogenicity of the mRNA vaccine BNT162b2 in patients with idiopathic pulmonary fibrosis
    Karampitsakos, Theodoros
    Papaioannou, Ourania
    Dimeas, Ilias
    Tsiri, Panagiota
    Sotiropoulou, Vasilina
    Tomos, Ioannis
    Papanikolaou, Ilias C.
    Katsaras, Matthaios
    Kirgou, Paraskevi
    Daniil, Zoe
    Gourgoulianis, Konstantinos I.
    Sampsonas, Fotios
    Manali, Effrosyni
    Papiris, Spyridon
    Bouros, Demosthenes
    Tzouvelekis, Argyris
    ERJ OPEN RESEARCH, 2022, 8 (02)
  • [8] Immunogenicity and safety of the mRNA-based BNT162b2 vaccine in systemic autoimmune rheumatic diseases patients
    Yael Pri-Paz Basson
    Oshrat E. Tayer-Shifman
    Rawand Naser
    Shelly Tartakover Matalon
    Oded Kimhi
    Raz Gepstein
    Tamar Halperin
    Tomer Ziv-Baran
    Amit Ziv
    Roma Parikh
    Shaye Kivity
    Yair Levy
    Clinical Rheumatology, 2022, 41 : 3879 - 3885
  • [9] Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine
    Payne, Rebecca P.
    Longet, Stephanie
    Austin, James A.
    Skelly, Donal T.
    Dejnirattisai, Wanwisa
    Adele, Sandra
    Meardon, Naomi
    Faustini, Sian
    Al-Taei, Saly
    Moore, Shona C.
    Tipton, Tom
    Hering, Luisa M.
    Angyal, Adrienn
    Brown, Rebecca
    Nicols, Alexander R.
    Gillson, Natalie
    Dobson, Susan L.
    Amini, Ali
    Supasa, Piyada
    Cross, Andrew
    Bridges-Webb, Alice
    Reyes, Laura Silva
    Linder, Aline
    Sandhar, Gurjinder
    Kilby, Jonathan A.
    Tyerman, Jessica K.
    Altmann, Thomas
    Hornsby, Hailey
    Whitham, Rachel
    Phillips, Eloise
    Malone, Tom
    Hargreaves, Alexander
    Shields, Adrian
    Saei, Ayoub
    Foulkes, Sarah
    Stafford, Lizzie
    Johnson, Sile
    Wootton, Daniel G.
    Conlon, Christopher P.
    Jeffery, Katie
    Matthews, Philippa C.
    Frater, John
    Deeks, Alexandra S.
    Pollard, Andrew J.
    Brown, Anthony
    Rowland-Jones, Sarah L.
    Mongkolsapaya, Juthathip
    Barnes, Eleanor
    Hopkins, Susan
    Hall, Victoria
    CELL, 2021, 184 (23) : 5699 - +
  • [10] Immunogenicity of BNT162b2 mRNA COVID-19 Vaccine in Patients with Cardiovascular Disease
    Naruse, Hiroyuki
    Ito, Hiroyasu
    Izawa, Hideo
    Sarai, Masayoshi
    Ishii, Junnichi
    Sakaguchi, Eirin
    Murakami, Reiko
    Ando, Tatsuya
    Fujigaki, Hidetsugu
    Saito, Kuniaki
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (23)
12345